on Biotest AG (isin : DE0005227201)
Biotest Reports 4.5% Revenue Increase in First Nine Months of 2024
Biotest AG has announced a 4.5% rise in revenues, reaching €523 million in the first nine months of 2024. The increase is attributed to strong product sales and toll manufacturing, which grew by 13.7% to €414 million, supported by the success of Yimmugo®.
The company's Group EBIT saw a decline to €71.1 million from €125.4 million the previous year, largely due to decreased contributions from technology transfer and development services with Grifols, S.A.
Biotest has also submitted a marketing authorization application for Fibrinogen Concentrate (BT524) in Germany, Austria, and Spain, anticipating approval by mid-2025.
While EBIT guidance remains steady, revenue expectations have been adjusted due to potential risks from geopolitical conflicts and economic instability.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biotest AG news